Correlation between thyroid hormone levels and the incidence and staging of bladder cancer

Table 3 Thyroid parameters in patients with different stages of bladder cancer

Parameter	Controls	NMIBC	MIBC	p-Value
n	27	29	17
Age	62.0 (60.0–68.0)	58.0 (52.0–67.0)	70.0 (60.5–75.5)	0.005^a
TSH (mIU/L)	1.88 (1.10–2.76)	2.61 (1.56–2.96)	2.58 (1.88–3.08)	0.058
TT3 (µg/L)	0.87 ± 0.25	1.09 ± 0.24	1.15 ± 0.28	< 0.001^bc
FT3 (pmol/L)	4.03 (3.57–4.63)	4.88 (4.15–5.23)	4.29 (3.93–4.87)	0.014^b
TT4 (µg/L)	65.60 (58.80–80.20)	87.00 (78.03–97.30)	83.55 (77.22–99.75)	< 0.001^bc
FT4 (pmol/L)	12.95 (12.33–16.39)	14.83 (13.46–16.82)	14.87 (12.40–17.32)	0.506
TGAb (IU/mL)	12.70 (0.00–16.17)	12.33 (0.00–16.54)	10.07 (0.00–14.78)	0.697
TPOAb (IU/mL)	16.00 (10.23–20.17)	8.30 (5.51–12.73)	6.91 (5.26–14.36)	0.002^bc
TG (ng/mL)	2.25 (1.18–4.18)	2.68(1.11–8.51)	6.15 (1.49–9.94)	0.190
TRAb (U/L)	3.65 (2.19–4.76)	2.82 (1.11–4.71)	3.12 (1.77–3.94)	0.524

The letters denote significant differences between groups as follows: a = significance between the NMIBC and MIBC groups; b = significance between the NMIBC patients and healthy controls, c = significance between the MIBC patients and healthy controls
The data are shown as the mean ± s.d. or median and quartiles (25–75%)
NMIBC non-muscle-invasive bladder cancer, MIBC muscle-invasive bladder cancer, TSH thyrotropin, TT3 total-triiodothyronine, FT3 free triiodothyronine, TT4 total thyroxine, FT4 free thyroxine, TGAb thyroglobulin antibody, TPOAb thyroid peroxidase antibodies, TG thyroglobulin, TRAb thyrotropin receptor antibody

ISSN: 2047-783X